Found 20 matching trials
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia PHASE1 This phase Ib/II trial studies the side effects and best dose of FT-2102 wh...
Show More Location
Multiple Locations
Learn More & Join Trial
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation PHASE1 This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2...
Show More Location
UCLA Medical Center
Learn More & Join Trial
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations PHASE2 To learn about the safety and tolerability of study drug combinations in pa...
Show More Location
MD Anderson Cancer Center
Learn More & Join Trial
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) PHASE2 This phase II MyeloMATCH treatment substudy tests the addition of olutaside...
Show More Location
Multiple Locations
Learn More & Join Trial
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant PHASE1 This phase I trial tests the safety, side effects, and effectiveness of olu...
Show More Location
City of Hope Medical Center
Learn More & Join Trial
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax PHASE2 This is a prospective, single-arm phase 2 pilot study to assess the respons...
Show More Location
Atrium Health Wake Forest Baptist Medical Center
Learn More & Join Trial
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent PHASE2 This phase II trial studies how well giving olutasidenib with azacitidine, ...
Show More Location
University of California Davis Comprehensive Cancer Center
Learn More & Join Trial
A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies PHASE2 The goal of this clinical research study is to learn about the safety and t...
Show More Location
The University of Texas M. D. Anderson Cancer Center
Learn More & Join Trial
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations PHASE1 This is an open-label, multi-center Phase 1 study of LY3410738, an oral, co...
Show More Status
Active Not Recruiting
Location
City of Hope National Medical Center
Learn More & Join Trial
Study of Olutasidenib and Temozolomide in HGG PHASE2 The goal of this study is to determine the efficacy of the study drug oluta...
Show More Location
Children's Hospital Colorado
Learn More & Join Trial